Clinical Trial: Study of BMS-986168 in Patients With Progressive Supranuclear Palsy

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants With Progressive

Brief Summary: The purpose of this study is to determine the efficacy and safety of intravenously administered BMS-986168 in participants with Progressive Supranuclear Palsy.

Detailed Summary:
Sponsor: Bristol-Myers Squibb

Current Primary Outcome:

  • Change in PSP (Progressive Supranuclear Palsy) Rating Scale [ Time Frame: Up to 52 Weeks ]
    Change from baseline
  • Frequency of Adverse Events [ Time Frame: Up to 52 Weeks ]
    Numbers and Percentages


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Bristol-Myers Squibb

Dates:
Date Received: February 27, 2017
Date Started: April 24, 2017
Date Completion: June 30, 2020
Last Updated: May 2, 2017
Last Verified: May 2017